|Bid||3.4965 x 30000|
|Ask||3.5300 x 30000|
|Day's Range||3.5655 - 3.5920|
|52 Week Range||3.5655 - 16.4000|
|Beta (5Y Monthly)||0.49|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 28, 2022 - Mar 04, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||13.22|
Subscribe to Yahoo Finance Plus to view Fair Value for GBMB.FLearn more
The heavy selling pressure might have exhausted for Inovio (INO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Ocugen jumped into the race to develop a vaccine for COVID-19 by partnering up with Bharat Biotech, an India-based biotech company. Bharat Biotech ran a late-stage clinical trial for the vaccine in question, Covaxin, in India, and earned emergency use authorization (EUA) for it there.
Compared to peers in the vaccine space, Inovio Pharmaceuticals’ (INO) DNA-based platform is somewhat unique. It could potentially boast the same hallmarks as mRNA vaccines – such as rapid modification, easy scale-up, no anti-vector immunity – but might also provide an improved safety and tolerability profile. And for that reason, Jefferies’ Roger Song thinks it the has the potential for “long-term value through a diverse pipeline.” This pipeline includes more than 15 different prophylactic/thera